Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/nri.2017.97 http://scihub22266oqcxt.onion/10.1038/nri.2017.97 C5816344!5816344 !28920587     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28920587 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28920587 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Nat+Rev+Immunol 2018 ; 18 (1 ): 5-18 Nephropedia Template TP {{tp|p=28920587 |t=2018. Complement in cancer: untangling an intricate relationship |pdf=|usr=}}{{28920587 }} gab.com Text Complement in cancer: untangling an intricate relationship JO: Nat Rev Immunol http://www.kidney.de/pget.php?&tw=1&pmid=28920587 #FOAvip In tumour immunology, complement has traditionally been considered as an adjunctive component that enhances the cytolytic effects of antibody-based immunotherapies, such as rituximab. Remarkably, research in the past decade has uncovered novel molecular mechanisms linking imbalanced complement activation in the tumour microenvironment with inflammation and suppression of antitumour immune responses. These findings have prompted new interest in manipulating the complement system for cancer therapy. This Review summarizes our current understanding of complement-mediated effector functions in the tumour microenvironment, focusing on how complement activation can act as a negative or positive regulator of tumorigenesis. It also offers insight into clinical aspects, including the feasibility of using complement biomarkers for cancer diagnosis and the use of complement inhibitors during cancer treatment. Twit Text FOAVip Complement in cancer: untangling an intricate relationship ????Nat Rev Immunol http://www.kidney.de/pget.php?&tw=1&pmid=28920587 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28920587 #FOAvip English Wikipedia <ref>{{Cite pmid|28920587 }}</ref> Complement in cancer: untangling an intricate relationship #MMPMID28920587 Reis ES ; Mastellos DC ; Ricklin D ; Mantovani A ; Lambris JD Nat Rev Immunol 2018[Jan]; 18 (1 ): 5-18 PMID28920587 show ga In tumour immunology, complement has traditionally been considered as an adjunctive component that enhances the cytolytic effects of antibody-based immunotherapies, such as rituximab. Remarkably, research in the past decade has uncovered novel molecular mechanisms linking imbalanced complement activation in the tumour microenvironment with inflammation and suppression of antitumour immune responses. These findings have prompted new interest in manipulating the complement system for cancer therapy. This Review summarizes our current understanding of complement-mediated effector functions in the tumour microenvironment, focusing on how complement activation can act as a negative or positive regulator of tumorigenesis. It also offers insight into clinical aspects, including the feasibility of using complement biomarkers for cancer diagnosis and the use of complement inhibitors during cancer treatment. |*Complement System Proteins [MESH] |*Neoplasms [MESH] |Chemotactic Factors [MESH] |Complement Activation [MESH] |Humans [MESH] |Myeloid Cells [MESH]Complement in cancer: untangling an intricate relationship (epmc).pdf DeepDyve Pubget Overpricing